Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines

British Journal of Cancer

Volumn 67, Issue 6, 1993, Pages 1316-1323

  Coley, H M ^a,b   Amos, W B ^b   Twentyman, P R ^a   Workman, P ^a,b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; GLYCOPROTEIN P; VERAPAMIL;

ANIMAL CELL; ARTICLE; BREAST CELL; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GOLGI COMPLEX; HUMAN CELL; LASER MICROSCOPY; LUNG CANCER; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMAL; ANTIBIOTICS, ANTHRACYCLINE; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; DOXORUBICIN; DRUG RESISTANCE; HUMAN; LASERS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICROSCOPY, FLUORESCENCE; P-GLYCOPROTEIN; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0027161768     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.244     Document Type: Article

References (33)

1. BARRAND, M.A., RHODES, T., CENTER, M.S. & TWENTYMAN, P R. (1993). Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer, 29A, 408-415.
2. COLEY, H.M., TWENTYMAN, PR. & WORKMAN, P. (1989a). Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug resistant cell lines and further resistance modification by verapamil and cyclosporin A. Cancer Chemother. Pharmacol., 24, 284-290.
3. COLEY, H.M., TWENTYMAN, P.R. & WORKMAN, P. (1989). Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem. Pharmacol., 38, 4467-4475.
4. COLEY, H.M., TWENTYMAN, P.R. & WORKMAN, P. (1990). 9-Alkyl morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur. J. Cancer, 26, 665-667.
5. COLEY, H.M., WORKMAN, P. & TWENTYMAN, P.R. (1991). Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br. J. Cancer, 63, 351-357.
6. DE DUVE, C., DE BARSYI, T., POOLE, B., TROUET, A., TULKENS, P. & VANHOOF, F. (1974). Lysosomotropic agents. Biochem. Pharmacol., 23, 2495-2551.
7. DIETEL, M. & SEIDEL, A. (1990). Morphologic alterations in drug sensitive vs drug resistant cells due to cytostatic application. Cancer Treat. Rev., 17, 3-10.
8. EGORIN, M.J., HILDEBRAND, R.C., CIMONO, E.F. & BACHUR, N.R. (1974). Cytofluorescence localisation of Adriamycin and Daunorubicin. Cancer Res., 34, 2243-2245.
9. EGORIN, M.J., CLAWSON, R.E., ROSS, L.A., SCHLOSSBERGER, N.M. & BACHUR, N.R. (1979). Cellular accumulation and disposition of aclacinomycin A. Cancer Res., 39, 4396-4676.
10. EGORIN, M.J., CLAWSON, R.E., COHEN, J.L., ROSS, L A. & BACHUR, N.R. (1980). Cytofluorescence localisation of anthracycline antibiotics. Cancer Res., 40, 4669-4676.
11. GERVASONI, J.E., FIELDS, S.Z., KRISHNA, S., BAKER, M.A., ROSADO, M., THURAISAMY, K., HINDENBURG, A.A. & TAUB, R.N. (1991). Subcellular distribution of daunorubicin in P- glycoprotein-positive and -negative drug resistant cell lines using laser-assisted confocal microscopy. Cancer Res., 51, 4955-4963.
12. GIGLI, M., RASOANAIVO, T.W.D., MILLOT, J.-M., JEANNESSON, P., RIZZO, V., JARDILLIER, J.-C., ARCAMONE, F. & MANFAIT, M. (1989). Correlation between growth inhibition and intranuclear doxorubicin and 4-deoxy-iodo-doxorubicin quantitated in living K562 cells by microspectrofluorimetry. Cancer Res., 49, 560-564.
13. HILL, B.T., DENNIS, L.Y., LI, X.T. & WHELAN, R.D.H. (1985). Identification of anthracycline analogues with enhanced cytoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother. Pharmacol., 14, 194-201.
14. HINDENBURG, A.A., GERVASONI, J.E., KRISHNA, S., STEWART, V.J., ROSADO, M., LUTZKY, J., BHALLA, K., BAKER, M.A. & TAUB, R.N. (1989). Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and - resistant HL-60 cells. Cancer Res., 49, 4607-4614.
15. KEIZER, H.G., SCHUURHUIS, G.J., BROXTERMAN, H.J., LANKELMA, J., SCHOONEN, W.G.E.J., VAN RIJN, J., PINEDO, H.M. & JOENJE, H. (1989). Correlation of multidrug resistance with decreased drug accumulation altered subcellular drug distribution and increased P-glycoprotein expression in cultured SW-1573 human lung tumour cells. Cancer Res., 49, 2988-2993.
16. KRISHAN, A., ISRAEL, M., MODEST, E.J. & FREI, E. (1976). Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyl adriamycin-14-valerate. Cancer Res., 36, 2108-2109.
17. LELONG, I.H., GUZIKOWSKI, A.P., HAUGLAND, R.P., PASTAN, I., GOTTESMAN, M.M. & WILLINGHAM, M. (1991). Fluorescent verapamil derivative for monitoring activity of multidrug transporter. Mol. Pharmacol., 40, 490-494.
18. LOTHSTEIN, L., SWEATMAN, T.W., DOCKTER, M E. & ISRAEL, M. (1992). Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N- benzyladriamycin-14-valerate accumulation. Cancer Res., 52, 3409-3417.
19. MARQUARDT, D. & CENTER, M.S. (1992). Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res., 52, 3157-3163.
20. MCGRATH, T. & CENTER, M.S. (1988). Mechanisms of multidrug resistance in HL-60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res., 48, 3559-3563.
21. REEVE, J.G., RABBITTS, P H. & TWENTYMAN, P.R. (1990). Non-P glycoprotein mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line. Br. J. Cancer, 61, 851-855.
22. ROSS, K.L., STOLINSKY, D.C. & TOKES, Z.A. (1986). Accumulation of adriamycin into cytoplasmic compartments by resistant L-1210 cells. Proc. Am. Assoc. Cancer Res., 27, 273.
23. SCHUURHUIS, G.J., BROXTERMAN, H.J., CERVANTES, A., VAN HEININGEN, T.H.M., DE LANGE, J.H.M., BAAK, J.P.A., PINEDO, H.M. & LANKELMA, J. (1989). Quantitative determination of factors contributing to doxorubicin resistance in multidrug- resistant cells. J. Natl Cancer Inst., 81, 1887-1892.
24. SCHUURHUIS, G.J., BROXTERMAN, J.H., DE LANGE, J.H.M., PINEDO, H.M., VAN HEININGEN, T.H.M., KUIPER, C.M., SCHEFFER, G.L., SCHEPER, R.J., VAN KALKEN, C.K., BAAK, J.P.A. & LANKELMA, J. (1991). Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J. Cancer, 64, 857-861.
25. SCOTT, C.A., WESTMACOTT, D., BROADHURST, M.J., THOMAS, G.J. & HALL, M.J. (1986). 9-Alkyl anthracyclines. Absence of crossresistance to adriamycin in human and murine cell cultures. Br. J. Cancer, 53, 595-600.
26. SHOJI, Y., FISHER, M.H., PERIASAMY, A., HERMAN, B. & JULIANO, R.L. (1991). Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms. Cancer Lett., 57, 209-218.
27. STREETER, D.G., TAYLOR, D.L., ACTON, E M. & PETERS, J.H. (1985). Comparative activities of various morpholinyl anthracyclines. Cancer Chemother. Pharmacol., 14, 160-164.
28. TSURUO, T., IIDA, H., KITATANI, Y., YOKOTA, K., TSUKAGOSHI, S. & SAKURAI, Y. (1984). Effect of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumour cells. Cancer Res., 44, 4303-4307.
29. TWENTYMAN, PR., FOX, N.E., WRIGHT, K.A., WORKMAN, P., BROADHURST, M.J., MARTIN, J.A. & BLEEHEN, N.M. (1986). The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br. J. Cancer, 53, 585-594.
30. TWENTYMAN, P.R., WRIGHT, K.A., REEVE, J.G. & KOCH, G. (1990). Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin). Br. J. Cancer, 62, 89-93.
31. WHITE, J.G., AMOS, W.B. & FORDHAM, M. (1987). An evaluation of confocal vs conventional imaging of biological structures by fluorescence light microscopy. J. Cell Biol., 105, 41-48.
32. WILLINGHAM, M., CORNWELL, M.M., CARARELLI, C O., GOTTESMAN, M.M. & PASTAN, I. (1986). Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and sensitive KB cells: effects of verapamil and other drugs. Cancer Res., 46, 5941-5946.
33. ZAMORA, J.M. & BECK, W.T. (1986). Potentiation of vinca alkaloid cytotoxicity by aminolines, acridines, indole alkaloids and aromatic amines. Proc. Am. Assoc. Cancer Res., 27, 395.